Page last updated: 2024-12-11

beta-elemene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

beta-elemene: increases tumor cell immunogenicity by inducing, at least in part, elevated expression of heat shock protein 70 on tumor cell surface [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

beta-elemene : A sesquiterpene that consists of cyclohexane bearing methyl and vinyl substituents at position 1 as well as two isopropenyl substituents at positions 2 and 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

(-)-beta-elemene : The (-)-enantiomer of beta-elemene that has (1S,2S,4R)-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6918391
CHEMBL ID448502
CHEBI ID62855
CHEBI ID62854
MeSH IDM0413550

Synonyms (52)

Synonym
sdp-111
levo-beta-elemene
cyclohexane, 2,4-diisopropenyl-1-methyl-1-vinyl-, (1s,2s,4r)-
cyclohexane, 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-, (1s-(1-alpha,2-beta,4-beta))-
beta-elemene, (-)-
(-)-beta-elemene
beta-elemen
beta-elemene
1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-cyclohexane
2,4-diisopropenyl-1-methyl-1-vinylcyclohexane
515-13-9
C17094
CHEMBL448502
chebi:62855 ,
(1s,2s,4r)-1-ethenyl-1-methyl-2,4-bis(prop-1-en-2-yl)cyclohexane
(1s,2s,4r)-1-ethenyl-1-methyl-2,4-di(prop-1-en-2-yl)cyclohexane
(1s,2s,4r)-2,4-diisopropenyl-1-methyl-1-vinylcyclohexane
(1s,2s,4r)-1-methyl-2,4-di(prop-1-en-2-yl)-1-vinylcyclohexane ,
(1s,2s,4r)-(-)-1-methyl-1-vinyl-2,4-diisopropenylcyclohexane
2qg8cx6lxd ,
unii-2qg8cx6lxd
EPITOPE ID:153551
S6957
cyclohexane, 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-, (1s,2s,4r)-
elemene, (-)-beta-
(-)-.beta.-elemene
beta elemene [who-dd]
elemene, (-)-.beta.-
.beta.-elemene
e- .beta.-elemene
OPFTUNCRGUEPRZ-QLFBSQMISA-N
AKOS028108977
(-)-beta-elemene, analytical standard
b-elemen
b-elemene
levo-b-elemene
(-)-b-elemene
HY-107324
CS-0028143
Q27132237
E79113
DTXSID60881211
levo-b-elemene(-)-b-elemene
DTXSID40865690
AS-82909
EN300-1709739
chebi:62854
rel-(1s,2s,4r)-1-ethenyl-1-methyl-2,4-di(prop-1-en-2-yl)cyclohexane
(-)-bete-elemene
rel-(1s,2s,4r)-1-methyl-2,4-di(prop-1-en-2-yl)-1-vinylcyclohexane
(1s,2s,4r)-beta-elemene
(1alpha,2beta,4beta)-1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)cyclohexane

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" beta-Elemene was administered at three doses (50, 75 and 100 mg/kg) and a full pharmacokinetic profile was obtained."( The pharmacokinetics of a novel anti-tumor agent, beta-elemene, in Sprague-Dawley rats.
Chen, Y; Li, Z; Su, C; Wang, K, 2005
)
1.49

Compound-Compound Interactions

This study was aimed to investigate the modulating effects on telomere length and telomerase activity in K562 cells treated by arsenic trioxide, ginseng saponin, beta-elemene alone or in combination with cyclophosphamide (CTX) Tumor growth was obviously inhibited and the survival period of the mice was obviously prolonged in beta- elemene combined with DC vaccine group.

ExcerptReferenceRelevance
" This study was to investigate the protective effects on murine pancreatic carcinoma by beta-elemene combined with bone marrow-derived dendritic cells (BM-DCs) modified with murine interleukin (IL)-23 gene."( [Immunotherapeutic effects of beta-elemene combined with interleukin-23 gene-modified dendritic cells on murine pancreatic carcinoma].
Cheng, L; Tan, G; Wang, XG; Wang, ZY; Yin, S, 2006
)
0.84
" Effects of vaccine combined with beta-elemene on tumor growth and survival period of the mice were observed."( [Immunotherapeutic effects of beta-elemene combined with interleukin-23 gene-modified dendritic cells on murine pancreatic carcinoma].
Cheng, L; Tan, G; Wang, XG; Wang, ZY; Yin, S, 2006
)
0.9
" Tumor growth was obviously inhibited and the survival period of the mice was obviously prolonged in beta-elemene combined with DC vaccine group than in DC, beta-elemene, or control group (P<0."( [Immunotherapeutic effects of beta-elemene combined with interleukin-23 gene-modified dendritic cells on murine pancreatic carcinoma].
Cheng, L; Tan, G; Wang, XG; Wang, ZY; Yin, S, 2006
)
0.84
"This study was aimed to investigate the modulating effects on telomere length and telomerase activity in K562 cells treated by arsenic trioxide, ginseng saponin, beta-elemene alone or in combination with cyclophosphamide (CTX) and to explore the possible mechanism and new therapy for acute leukemia."( Effect of ginseng saponin, arsenic trioxide, beta-elemene combined with CTX on telomere-telomerase system in K562 cell line.
Fang, MY; Wang, Y, 2006
)
0.79
" Cisplatin combined with β-elemene as a chemosensitizer or adjuvant warrants further study and may be potentially useful as a first-line treatment of androgen-independent prostate carcinomas."( Evaluation of cisplatin in combination with β-elemene as a regimen for prostate cancer chemotherapy.
Cuff, CF; Huang, L; Li, QQ; Reed, E; Wang, G, 2010
)
0.36
"In this study, we aimed to analyze the anti-cancer effects of β-elemene combined with paclitaxel for ovarian cancer."( Treatment with β-elemene combined with paclitaxel inhibits growth, migration, and invasion and induces apoptosis of ovarian cancer cells by activation of STAT-NF-κB pathway.
Dandan, Y; Jinghong, A; Juan, J; Lei, L; Qi, Y; Xiaomeng, F, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
"The bioavailability of PVP coated beta-elemene liposomes is 140."( [Study on pharmacokinetics of PVP coated beta-elemene liposome in rats].
Deng, YJ; Gao, XF; Li, Z; Wang, XM; Zhang, XY; Zhao, CJ, 2006
)
0.88
" In addition, β-E-NLCs showed a significantly higher bioavailability and anti-tumor efficacy than Elemene injection."( Formulation design, preparation, and in vitro and in vivo characterizations of β-Elemene-loaded nanostructured lipid carriers.
Du, Y; Feng, N; Guo, T; Ren, J; Shi, F; Yang, G, 2013
)
0.39

Dosage Studied

Less dosage and shorter course can be expected when arsenic trioxide, ginseng saponin, and beta-elemene are used in combination with CTX.

ExcerptRelevanceReference
"After a single administration of beta-elemene to rats at the dosage of 75 mg x kg(-1) (i."( [Excretion of beta-elemene from rat respiratory tracts].
Chen, YR; Li, SY; Li, Z; Su, CY; Wang, K; Wu, XY, 2005
)
0.97
" Less dosage and shorter course can be expected when arsenic trioxide, ginseng saponin, and beta-elemene are used in combination with CTX."( Effect of ginseng saponin, arsenic trioxide, beta-elemene combined with CTX on telomere-telomerase system in K562 cell line.
Fang, MY; Wang, Y, 2006
)
0.81
" The apoptosis of T24 cells is dependent on the dosage and length of incubation time of β-elemene."( β-elemene acts as an antitumor factor and downregulates the expression of survivin, Bcl-xL and Mta-1.
Chen, X; Ding, J; Long, X; Luo, H; Luo, Z; Qiu, W; Wang, Y; Xie, H; Yang, L; Yang, N; Zhang, B; Zhang, T, 2012
)
0.38
" In this study, we found that β-elemene, which alone had little effect on hepatocellular carcinoma (HCC) cell proliferation, exerted a synergistic anti-proliferative effect in HCC cells when dosed in combination with oxaliplatin, which increased the amounts of platinum accumulation and platinum-DNA adduct significantly and augmented the oxaliplatin-induced apoptosis."( β-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1.
Guo, L; Li, H; Li, X; Lin, Z; Liu, S; Ye, Q; Zhang, B; Zhang, J, 2016
)
0.43
" As the flexible complex liposome, the dosage of cabazitaxel could be reduced to 25% that of the cabazitaxel injection while retaining a similar therapeutic effect."( The Preparation, Determination of a Flexible Complex Liposome Co-Loaded with Cabazitaxel and β-Elemene, and Animal Pharmacodynamics on Paclitaxel-Resistant Lung Adenocarcinoma.
Li, CX; Xie, T; Zeng, YJ; Zeng, YY; Zeng, ZW; Zhang, NN, 2019
)
0.51
" ACE2 expression was down-regulated with the treatment of β-elemene at different dosage point."( β-elemene affects angiogenesis of infantile hemangioma by regulating angiotensin-converting enzyme 2 and hypoxia-inducible factor-1 alpha.
Du, C; Tao, B; Wang, Z; Xian, H; Zhang, Y, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
beta-elemeneA sesquiterpene that consists of cyclohexane bearing methyl and vinyl substituents at position 1 as well as two isopropenyl substituents at positions 2 and 4.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
u03B2-caryophyllene biosynthesis75
u03B2-caryophyllene biosynthesis85

Bioassays (20)

Assay IDTitleYearJournalArticle
AID1848136Antiproliferative activity against human U-251 cells assessed as inhibition of cell growth measured after 48 hrs by CCK8 assay relative to control2022Bioorganic & medicinal chemistry, 11-15, Volume: 74Design, synthesis and antitumor efficacy evaluation of a series of novel β-elemene-based macrocycles.
AID1179744Antioxidant activity in HUVEC assessed as suppression of ROS production by measuring fluorescent intensity index at 5 uM pre-incubated for 24 hrs before H2O2 stimulation for 2 hrs by DCF dye based fluorimetric assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Design, synthesis and antioxidant activity evaluation of novel β-elemene derivatives.
AID1881907Inhibition of PKM2 (unknown origin) Gly128, Ser205, Hie78, Gly363, Ala366 residues2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.
AID1848130Antiproliferative activity against human U-87 MG cells assessed as inhibition of cell growth at 50 uM measured after 48 hrs by CCK8 assay relative to control2022Bioorganic & medicinal chemistry, 11-15, Volume: 74Design, synthesis and antitumor efficacy evaluation of a series of novel β-elemene-based macrocycles.
AID1484985Antiproliferative activity against human SGC7901 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Discovery of novel antitumor nitric oxide-donating β-elemene hybrids through inhibiting the PI3K/Akt pathway.
AID1179745Antioxidant activity in HUVEC assessed as suppression of ROS production by measuring fluorescent intensity index at 10 uM pre-incubated for 24 hrs before H2O2 stimulation for 2 hrs by DCF dye based fluorimetric assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Design, synthesis and antioxidant activity evaluation of novel β-elemene derivatives.
AID1848127Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth at 50 uM measured after 48 hrs by CCK8 assay relative to control2022Bioorganic & medicinal chemistry, 11-15, Volume: 74Design, synthesis and antitumor efficacy evaluation of a series of novel β-elemene-based macrocycles.
AID1848131Antiproliferative activity against human U-251 cells assessed as inhibition of cell growth at 50 uM measured after 48 hrs by CCK8 assay relative to control2022Bioorganic & medicinal chemistry, 11-15, Volume: 74Design, synthesis and antitumor efficacy evaluation of a series of novel β-elemene-based macrocycles.
AID1848134Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by CCK8 assay relative to control2022Bioorganic & medicinal chemistry, 11-15, Volume: 74Design, synthesis and antitumor efficacy evaluation of a series of novel β-elemene-based macrocycles.
AID1848135Antiproliferative activity against human U-87 MG cells assessed as inhibition of cell growth measured after 48 hrs by CCK8 assay relative to control2022Bioorganic & medicinal chemistry, 11-15, Volume: 74Design, synthesis and antitumor efficacy evaluation of a series of novel β-elemene-based macrocycles.
AID368014Cell cycle arrest in human HeLa cells assessed as increase in G1 phase cells after 24 hrs by flow cytometry using propidium iodide staining2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Synthesis and in vitro anti-proliferative activity of beta-elemene monosubstituted derivatives in HeLa cells mediated through arrest of cell cycle at the G1 phase.
AID1484986Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Discovery of novel antitumor nitric oxide-donating β-elemene hybrids through inhibiting the PI3K/Akt pathway.
AID1485018Toxicity in ICR mouse xenografted with human H22 cells assessed as body weight at 60 mg/kg, iv administered qd for 3 weeks (Rvb = 22.9 +/- 0.4 g)2017European journal of medicinal chemistry, Jul-28, Volume: 135Discovery of novel antitumor nitric oxide-donating β-elemene hybrids through inhibiting the PI3K/Akt pathway.
AID368013Antiproliferative activity against human HeLa cells after 24 hrs by WST-1 assay2009Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3
Synthesis and in vitro anti-proliferative activity of beta-elemene monosubstituted derivatives in HeLa cells mediated through arrest of cell cycle at the G1 phase.
AID1485016Antitumor activity against human H22 cells xenografted in ICR mouse assessed as tumor growth inhibition at 60 mg/kg, iv qd for 3 weeks relative to control2017European journal of medicinal chemistry, Jul-28, Volume: 135Discovery of novel antitumor nitric oxide-donating β-elemene hybrids through inhibiting the PI3K/Akt pathway.
AID1848129Antiproliferative activity against human A549 cells assessed as inhibition of cell growth at 50 uM measured after 48 hrs by CCK8 assay relative to control2022Bioorganic & medicinal chemistry, 11-15, Volume: 74Design, synthesis and antitumor efficacy evaluation of a series of novel β-elemene-based macrocycles.
AID1848133Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by CCK8 assay relative to control2022Bioorganic & medicinal chemistry, 11-15, Volume: 74Design, synthesis and antitumor efficacy evaluation of a series of novel β-elemene-based macrocycles.
AID1848128Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth at 50 uM measured after 48 hrs by CCK8 assay relative to control2022Bioorganic & medicinal chemistry, 11-15, Volume: 74Design, synthesis and antitumor efficacy evaluation of a series of novel β-elemene-based macrocycles.
AID1848132Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth measured after 48 hrs by CCK8 assay relative to control2022Bioorganic & medicinal chemistry, 11-15, Volume: 74Design, synthesis and antitumor efficacy evaluation of a series of novel β-elemene-based macrocycles.
AID1484987Antiproliferative activity against human U87 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Discovery of novel antitumor nitric oxide-donating β-elemene hybrids through inhibiting the PI3K/Akt pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (256)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (0.78)18.2507
2000's37 (14.45)29.6817
2010's159 (62.11)24.3611
2020's58 (22.66)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.39 (24.57)
Research Supply Index5.56 (2.92)
Research Growth Index5.91 (4.65)
Search Engine Demand Index42.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.39%)5.53%
Reviews12 (4.65%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other245 (94.96%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]